LIXTClinical Trials•globenewswire•
24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy
Sentiment:Positive (70)
Summary
LIXTE (NASDAQ: LIXT) publishes new data showing that its lead compound LB-100 can mediate activation of oncogenic signaling, which is toxic to cancer cells
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 27, 2025 by globenewswire